Generic Drugs: Last Week Tonight with John Oliver (HBO)

Overview

John Oliver examines the benefits and vulnerabilities of generic drugs. Generics contain the same active ingredients as brand-name drugs and are intended to match them in dosage, strength, safety, quality, and use.

They account for more than 90% of U.S. prescriptions and have saved patients and the health-care system trillions of dollars, often substantially reducing prices.

Risks of Low Prices and Supply Shortages

The program argues that relentless pressure to lower prices can leave too few manufacturers producing essential medicines. If a manufacturer exits the market or has a production problem, shortages can follow.

The segment cites shortages of heparin and chemotherapy drugs, including vincristine and cisplatin. Shortages can delay treatment and put patients at risk. The American Medical Association has called drug shortages a public-health crisis and a national-security threat.

Manufacturing Quality and Oversight

The show raises concerns about manufacturing quality and regulatory oversight. Much of the U.S. drug supply is made overseas, and studies and testing have found problems such as contamination, incorrect dosage, and drugs that do not dissolve or work as expected.

A heart-transplant recipient described dangerous swings in levels of generic tacrolimus after switching manufacturers. In another case, contaminated eye drops made in India were linked to deaths, vision loss, and eye removals.

Oliver says FDA inspections are limited by staffing and resources, and overseas inspections are often announced in advance. He highlights troubling inspection findings at facilities run by Intas and Hetero. When regulators restrict a factory, they may grant exceptions to avoid worsening shortages—sometimes allowing drugs from facilities with known quality concerns to continue reaching the United States.

The segment notes that the FDA has defended its efforts while acknowledging that its authority and oversight could be strengthened.

Proposed Responses

The segment discusses several possible responses:

• Produce critical drugs and their active ingredients in the United States or allied countries.
• Give the FDA more resources for surprise inspections and targeted testing.
• Create a public quality-rating system to reward reliable manufacturers.

Advice for Consumers

Oliver stresses that people should not stop taking prescribed medication: most generics are safe. If a medication seems to be working differently, patients can ask whether its manufacturer has changed.

He also points to ProPublica’s RX Inspector tool, which provides information about manufacturers and facility inspection histories.

People Mentioned

• Presenter: John Oliver
• Contributors featured in news clips: Patients and family members, clinicians, a pharmacy-services director, and a former FDA inspector. These contributors are not named in the subtitles.
• Also mentioned: Kevin Bacon and Kyra Sedgwick, in connection with advocacy; they are not featured as substantive contributors.